The SPINK2 Knockout THP-1 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from human THP-1 monocytes, featuring targeted disruption of the SPINK2 gene. This loss-of-function model enables investigation of SPINK2’s role in serine protease inhibition, NF-??B signaling, and macrophage function in a leukemic background.
The parental THP-1 cell line originates from a 1-year-old male with acute monocytic leukemia and is widely used to study monocyte-macrophage differentiation and inflammatory responses. THP-1 cells are PTEN-null, p53-null, and harbor the MLL-AF9 fusion oncogene, making them a valuable system for dissecting pathways relevant to myeloid biology and leukemogenesis.
SPINK2 encodes a Kazal-type serine protease inhibitor that directly binds and inhibits trypsin, acrosin, neutrophil elastase, and proteinase-3. It is transcriptionally upregulated by androgens and by inflammatory cytokines TNF-?? and IL-1?? through NF-??B, forming a negative feedback loop. Loss of SPINK2 removes restraint on these proteases, leading to unchecked proteolytic activity that activates the IKK complex. Subsequent NF-??B nuclear translocation enhances expression of pro-inflammatory cytokines, amplifying the inflammatory response. Thus, SPINK2 normally functions to temper protease-driven inflammation, and its disruption unleashes a feed-forward cycle of cytokine production and protease activation.
In the THP-1 knockout, enhanced serine protease activity is predicted to potentiate NF-??B signaling and increase inflammatory mediator output. This dysregulation may alter macrophage polarization, phagocytosis, and leukemic cell survival or proliferation. By eliminating SPINK2-mediated inhibition, the model enables dissection of the crosstalk between proteolytic cascades and inflammatory gene programs in a leukemia-relevant context. It also serves to explore how aberrant protease signaling contributes to acute myeloid leukemia pathogenesis and inflammation-associated disorders.
Researchers can utilize this cell line in Western blotting, RT-qPCR, and flow cytometry (CD11b, CD14, CD68) to monitor NF-??B pathway activity and macrophage differentiation. ELISA assays for TNF-??, IL-6, and IL-1??, along with NF-??B luciferase reporters and serine protease activity measurements, allow quantitative assessment of signaling output. Further applications include RNA-seq transcriptome profiling, cell viability assays under inflammatory challenge, and drug response screens. This knockout model supports mechanistic and translational studies in inflammation and leukemia. For more information, please contact Ascent Research.
